25 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020

SYNRIBO is a drug marketed by Teva Pharms Intl. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in nineteen countries.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the omacetaxine mepesuccinate profile page.

IONSYS is a drug marketed by The Medicines Co. There are eleven patents protecting this drug.

This drug has one hundred and sixty-eight patent family members in thirty-three countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fentanyl hydrochloride profile page.

POMALYST is a drug marketed by Celgene. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty-one patent family members in forty-five countries. There has been litigation on patents covering POMALYST

See drug price trends for POMALYST.

The generic ingredient in POMALYST is pomalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pomalidomide profile page.

JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.

This drug has ninety-one patent family members in thirty-seven countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

ABLAVAR is a drug marketed by Lantheus Medcl. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-six countries.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

FORTOVASE is a drug marketed by Hoffmann La Roche. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this API. Additional details are available on the saquinavir profile page.

EGRIFTA is a drug marketed by Theratechnologies. There are five patents protecting this drug.

This drug has forty-four patent family members in sixteen countries.

See drug price trends for EGRIFTA.

The generic ingredient in EGRIFTA is tesamorelin acetate. One supplier is listed for this generic product. Additional details are available on the tesamorelin acetate profile page.

XTORO is a drug marketed by Merlion Pharms Gmbh. There are three patents protecting this drug.

This drug has thirty-nine patent family members in eighteen countries.

The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.

VIMOVO is a drug marketed by Horizon. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-three countries. There has been litigation on patents covering VIMOVO

See drug price trends for VIMOVO.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the esomeprazole magnesium; naproxen profile page.

VYXEOS is a drug marketed by Celator Pharms. There are eight patents protecting this drug.

This drug has one hundred and nine patent family members in twenty-one countries.

See drug price trends for VYXEOS.

The generic ingredient in VYXEOS is cytarabine; daunorubicin . There are fifteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cytarabine; daunorubicin profile page.

CIPRODEX is a drug marketed by Novartis Pharms Corp. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty-two countries. There has been litigation on patents covering CIPRODEX

See drug price trends for CIPRODEX.

The generic ingredient in CIPRODEX is ciprofloxacin; dexamethasone. There are thirty-four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ciprofloxacin; dexamethasone profile page.

SOLAGE is a drug marketed by Almirall. There is one patent protecting this drug.

This drug has thirteen patent family members in twelve countries.

The generic ingredient in SOLAGE is mequinol; tretinoin. Additional details are available on the mequinol; tretinoin profile page.

DOTAREM is a drug marketed by Guerbet.

This drug has thirteen patent family members in twelve countries.

See drug price trends for DOTAREM.

The generic ingredient in DOTAREM is gadoterate meglumine. One supplier is listed for this generic product. Additional details are available on the gadoterate meglumine profile page.

BIDIL is a drug marketed by Arbor Pharms Llc. There are two patents protecting this drug.

This drug has four patent family members in four countries.

See drug price trends for BIDIL.

The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.

RAPIVAB is a drug marketed by Biocryst. There are three patents protecting this drug.

This drug has sixty-three patent family members in twenty-eight countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

THALOMID is a drug marketed by Celgene. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has forty-seven patent family members in nineteen countries. There has been litigation on patents covering THALOMID

See drug price trends for THALOMID.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the thalidomide profile page.

ESKATA is a drug marketed by Aclaris. There are four patents protecting this drug.

This drug has twenty-six patent family members in fifteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydrogen peroxide profile page.